Daily Stock Analysis, BDSI, BioDelivery Sciences International Inc, priceseries

BioDelivery Sciences International Inc. Daily Stock Analysis
Stock Information
Open
4.68
Close
4.62
High
4.70
Low
4.50
Previous Close
4.65
Daily Price Gain
-0.03
YTD High
5.37
YTD High Date
Apr 1, 2019
YTD Low
3.52
YTD Low Date
Jan 2, 2019
YTD Price Change
0.97
YTD Gain
26.58%
52 Week High
5.37
52 Week High Date
Apr 1, 2019
52 Week Low
1.70
52 Week Low Date
May 11, 2018
52 Week Price Change
2.45
52 Week Gain
112.41%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 12. 2017
1.90
May 31. 2017
2.24
12 Trading Days
17.97%
Link
LONG
Jun 19. 2017
2.35
Jun 30. 2017
2.66
9 Trading Days
13.17%
Link
LONG
Jul 20. 2017
3.15
Aug 2. 2017
3.32
9 Trading Days
5.52%
Link
LONG
Nov 27. 2017
2.45
Dec 14. 2017
2.66
13 Trading Days
8.42%
Link
LONG
May 16. 2018
1.95
Jun 18. 2018
2.81
22 Trading Days
43.89%
Link
LONG
Sep 28. 2018
2.80
Oct 22. 2018
3.54
16 Trading Days
26.31%
Link
LONG
Dec 28. 2018
3.29
Jan 22. 2019
4.11
15 Trading Days
24.91%
Link
Company Information
Stock Symbol
BDSI
Exchange
NasdaqCM
Company URL
http://www.bdsi.com
Company Phone
919 582 9050
CEO
Mark A. Sirgo
Headquarters
North Carolina
Business Address
4131 PARKLAKE AVENUE, SUITE 225, RALEIGH, NC 27612
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001103021
About

BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC.

Description

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, erodible polymer film for application to the buccal mucosa. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA, a buprenorphine buccal film for the treatment of chronic pain. The company also develops Buprenorphine Depot Injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. It has a licensing and development agreement with Endo Pharmaceuticals, Inc.; Evonik Corporation; Collegium Pharmaceutical, Inc.; and Meda AB. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.